Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process

Results in Immunology

Volumn 2, Issue , 2012, Pages 19-24

  Dichtelmüller, Herbert O ^a   Flechsig, Eckhard ^a   Sananes, Frank ^b   Kretschmar, Michael ^a   Dougherty, Christopher J ^b  

^a BIOTEST AG   (Germany)

^b Biotest Pharmaceuticals   (United States)

Author keywords

Cold ethanol fractionation; Intravenous immunoglobulin; Low pH; Solvent detergent; Virus filtration; Virus inactivation

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; BOCAVIRUS; BOVINE DIARRHEA VIRUS; CRYOPRECIPITATION; DRUG MANUFACTURE; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PH; PORCINE PARVOVIRUS; PRECIPITATION; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; SIMIAN VIRUS 40; SINDBIS VIRUS; VIRUS INACTIVATION; VIRUS TITRATION; WEST NILE FLAVIVIRUS;

EID: 84858225032     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.01.002     Document Type: Article

References (23)

1. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products; WHO Technical Report series no. 924, 2004.
2. Guideline on Plasma Derived Medicinal Products; CPMP/BWP/269/95, rev. 3, 25 January 2001.
3. Cavalli-Sforza L. Biometrie Grundzuge Biologisch-medizinischer Statistik [Biometry, the basics of biological and medical statistics] 1974, Gustav Fischer, Stuttgart, [p. 171-3].
4. Dichtelmüller H.O., Biesert L., Fabbrizzi F., Falbo A., Flechsig E., Gröner A., et al. Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2011, 51:1412-1430.
5. Prince A.M., Horowitz B., Horowitz M.S., Zang E. The development of virus-free labile blood derivatives-a review. European Journal of Epidemiology 1987, 3:103-118.
6. Prince A.M., Horowitz B., Brotman B., Huima T., Richardson L., van den Ende M. Inactivation of Hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sanguinis 1984, 46:36-43.
7. Prince A.M., Horowitz B., Dichtelmüller H., Stephan W., Gallo R.C. Quantitative assays for evaluation of HTLV III inactivation procedures: tri(N-butyl) phosphate:sodium cholate and Β-propiolactone. Cancer Research 1985, 45:4592s-4594ss.
8. Horowitz B., Wiebe M.E., Lippin A., Stryker M.H.G. Inactivation of viruses in labile blood products I. Disruption of lipid enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion 1985, 25:516-522.
9. Alonso W.R., Trukawinski S., Savage M., Tenold R.A., Hammond D.J. Viral inactivation of intramuscular immune serum globulins. Biologicals 2000, 28:5-15.
10. Biesert L. Virus validation studies of immunoglobulin preparations. Clinical and Experimental Rheumatology 1996, 14(Suppl. 15):s47-s52.
11. Rabenau H.F., Biesert L., Schmidt T., Bauer G., Cinatl J., Doerr H.W. SARS-corona virus (SARS-CoV) and the safety of a solvent/detergent treated immunoglobulin preparation. Biologicals 2005, 33:95-99.
12. Dichtelmüller H.O., Biesert L., Fabbrizzi F., Gajardo R., Gröner A., von Hoegen I., et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009, 49:1931-1943.
13. Reid K.G., Cuthbertson B., Jones A.D.L., McIntosh R.V. Potential contribution of mild pepsintreatment at pH 4 to the viral safety of human immunoglobulin products. Vox Sanguinis 1988, 55:75-80.
14. Omar A., Kempf C., Immelmann A., Rentsch M., Morgenthaler J.J. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation. Transfusion 1996, 36:866-872.
15. Louie R.E., Galloway C.J., Dumas M.L., Wong M.F., Mitra G. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994, 22:13-19.
16. Bos O.J.M., Sunye D.G.J., Nieuweboer C.E.F., van Engelenburg F.A.C., Schuitemaker H., Over J. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn Fractionation Process. Biologicals 1998, 26:267-276.
17. Troccoli N.M., McIver J., Losikoff A., Poiley J. Removal of viruses from human intravenous immune globulin by 35nm nanofiltration. Biologicals 1998, 26:321-329.
18. ® DIF, a new pasteurized, solvent-detergent treated and Planova 20nm nanofiltered intravenous immunoglobulin. Biologicals 2010, 38:486-493.
19. Poelsler G., Berting A., Kindermann J., Spruth M., Hämmerle T., Teschner W., et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sanguinis 2008, 94:184-192.
20. Lee D.C., Stenland C.J., Miller J.L.C., Cai K., et al. A direct relationship between partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2000, 41:449-455.
21. Foster P.R., Welch A.G., McLean C., Griffin B.D., et al. Distribution of a bovine spongiform encephalopathy - derived agent over ion - exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sanguinis 2004, 86:92-99.
22. Yunoki M., Tanaka H., Urayama T., Hattori S., et al. Prion removal by nanofiltration under different experimental conditions. Biologicals 2008, 36(1):27-36.
23. Brown P. Donor pool size and the risk of blood-borne Creutzfeldt-Jakob disease. Transfusion 1998, 38(3):312-315.